Squarepoint
TARA icon

Squarepoint’s Protara Therapeutics TARA Stock Holding History

Squarepoint’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.2K Buy
+18,124
New +$86.2K ﹤0.01% 4245
2026
Q1 		– Sell
-12,692
Closed -$67.6K – 4952
2025
Q4 		$67.6K Buy
12,692
+307
+2% +$1.71K ﹤0.01% 4102
2025
Q3 		$53.9K Sell
12,385
-11,989
-49% -$38.8K ﹤0.01% 4215
2025
Q2 		$73.9K Buy
24,374
+12,142
+99% +$41.9K ﹤0.01% 4239
2025
Q1 		$52.1K Sell
12,232
-8,523
-41% -$38.1K ﹤0.01% 4338
2024
Q4 		$110K Buy
+20,755
New +$67.1K ﹤0.01% 4677

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Squarepoint's TARA Position: Q2 2026 in Review

Squarepoint opened a new position in Protara Therapeutics (TARA) in Q2 2026: 18,124 shares worth $69.2K. The stake represents ﹤0.01% of the portfolio and ranks #4245 among its holdings. This is a return to the name: Squarepoint previously reported a position in TARA as recently as Q4 2025.

Squarepoint first reported a position in TARA in Q4 2024 and has held it in 6 quarters since. The position peaked at $110K in Q4 2024. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Squarepoint held 18,124 shares of Protara Therapeutics worth $69.2K as of Q2 2026.
  • Protara Therapeutics was a new Squarepoint position in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4245 holding.
  • Squarepoint first reported a position in Protara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Squarepoint's Protara Therapeutics position peaked at $110K in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.